Alimera Sciences (STU:ASZ1) Short-Term Debt : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Alimera Sciences Short-Term Debt?

Alimera Sciences's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.00 Mil.

Alimera Sciences's annual Short-Term Debt increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€23.90 Mil) but then declined from Dec. 2022 (€23.90 Mil) to Dec. 2023 (€0.00 Mil).

Alimera Sciences Short-Term Debt Historical Data

The historical data trend for Alimera Sciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Short-Term Debt Chart

Alimera Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

1.22

23.90

Alimera Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Alimera Sciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Alimera Sciences Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Alimera Sciences (STU:ASZ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (STU:ASZ1) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

ALIM:USA ASZ1:Germany

Address

6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005

Website

https://www.alimerasciences.com

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (STU:ASZ1) Headlines

No Headlines